Moderna, Inc. $MRNA Shares Sold by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board reduced its stake in Moderna, Inc. by 19.0%, resulting in ownership of approximately $10.44 million worth of shares.
• Moderna's recent earnings report showed a quarterly revenue of $142 million, exceeding expectations, but the company reported a loss per share of ($2.13).
• Analysts currently have a consensus rating of "Hold" on Moderna, with an average target price of $42.88.

Canada Pension Plan Investment Board decreased its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 19.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 368,272 shares of the company's stock after selling 86,135 shares during the quarter. Canada Pension Plan Investment Board owned approximately 0.10% of Moderna worth $10,441,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Deseret Mutual Benefit Administrators increased its position in Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after buying an additional 392 shares in the last quarter. Parallel Advisors LLC lifted its position in Moderna by 11.4% during the first quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock valued at $125,000 after purchasing an additional 451 shares in the last quarter. Blue Sky Capital Consultants Group Inc. lifted its holdings in Moderna by 3.8% during the first quarter. Blue Sky Capital Consultants Group Inc. now owns 15,119 shares of the company's stock valued at $429,000 after purchasing an additional 556 shares in the last quarter. Empirical Finance LLC boosted its holdings in Moderna by 7.3% in the 1st quarter. Empirical Finance LLC now owns 9,215 shares of the company's stock worth $261,000 after buying an additional 624 shares during the period. Finally, Xponance Inc. raised its stake in Moderna by 1.4% during the 1st quarter. Xponance Inc. now owns 45,412 shares of the company's stock valued at $1,287,000 after purchasing an additional 642 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on MRNA. Leerink Partners lowered their target price on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research report on Friday, August 22nd. Citigroup assumed coverage on shares of Moderna in a research note on Friday, August 1st. They set a "neutral" rating and a $40.00 price target for the company. Bank of America cut their price target on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research note on Tuesday, July 22nd. JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a report on Friday, August 1st. Finally, Cowen initiated coverage on shares of Moderna in a report on Sunday, July 13th. They set a "hold" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of "Hold" and a consensus price target of $42.88.

Moderna Stock Up 1.0%

Shares of MRNA traded up $0.23 during mid-day trading on Thursday, hitting $24.28. 9,148,047 shares of the company traded hands, compared to its average volume of 8,993,171. The company has a market capitalization of $9.45 billion, a PE ratio of -3.22 and a beta of 1.93. The business has a 50 day moving average of $28.88 and a 200 day moving average of $28.63. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $79.96.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the previous year, the firm earned ($3.33) EPS. Moderna's revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.